Loading...
XOSLBGBIO
Market cap28mUSD
Dec 23, Last price  
8.42NOK
1D
0.84%
1Q
-15.72%
IPO
-96.94%
Name

Bergenbio ASA

Chart & Performance

D1W1MN
XOSL:BGBIO chart
P/E
—
P/S
929.70
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
24.83%
Rev. gr., 5y
-31.43%
Revenues
354k
-9.00%
598,0000002,335,0008,900,000601,000774,000389,000354,000
Net income
-190m
L-36.24%
-57,780,000-72,107,000-129,799,000-182,208,000-191,747,000-199,387,000-257,061,000-309,417,000-298,609,000-190,401,000
CFO
-225m
L-21.90%
-53,715,000-62,902,000-124,314,000-168,109,000-186,706,000-184,145,000-234,290,000-303,340,000-288,231,000-225,101,000
Earnings
Feb 19, 2025

Profile

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
URL
https://www.bergenbio.com/
IPO date
Apr 07, 2017
Employees
28
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
354
-9.00%
389
-49.74%
774
28.79%
Cost of revenue
107,786
8,340
25,488
Unusual Expense (Income)
NOPBT
(107,432)
(7,951)
(24,714)
NOPBT Margin
Operating Taxes
(3,513)
53
Tax Rate
NOPAT
(107,432)
(4,438)
(24,767)
Net income
(190,401)
-36.24%
(298,609)
-3.49%
(309,417)
20.37%
Dividends
Dividend yield
Proceeds from repurchase of equity
262,048
3,218
16,629
BB yield
-65.86%
-0.49%
-0.93%
Debt
Debt current
418
681
Long-term debt
418
550
2,565
Deferred revenue
Other long-term liabilities
(1,000)
Net debt
(155,585)
(149,521)
(432,644)
Cash flow
Cash from operating activities
(225,101)
(288,231)
(303,340)
CAPEX
Cash from investing activities
3,055
3,248
3,130
Cash from financing activities
224,884
2,904
15,995
FCF
(107,820)
(3,290)
(23,627)
Balance
Cash
156,421
150,071
435,890
Long term investments
Excess cash
156,403
150,052
435,851
Stockholders' equity
79,635
8,866
8,846
Invested Capital
48,259
79,907
377,203
ROIC
ROCE
EV
Common stock shares outstanding
14,313
7,726
7,666
Price
27.80
-67.56%
85.70
-63.17%
232.67
-37.02%
Market cap
397,902
-39.90%
662,096
-62.88%
1,783,759
-26.06%
EV
242,317
512,575
1,351,115
EBITDA
(107,209)
(7,068)
(23,402)
EV/EBITDA
Interest
578
321
53
Interest/NOPBT